Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De‐Escalation in Adults With Inflammatory Bowel Diseases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De‐Escalation in Adults With Inflammatory Bowel Diseases

Published:2019-04-29 Issue:3 Volume:106 Page:605-615
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Petitcollin Antoine¹²³,Brochard Charlène⁴⁵,Siproudhis Laurent⁴⁵,Tron Camille¹²³,Verdier Marie‐Clémence¹²³,Lemaitre Florian¹²³,Lucidarme Camille⁵,Bouguen Guillaume⁴⁵,Bellissant Éric¹²³

Affiliation:

1. Department of Clinical and Biological Pharmacology Pharmacovigilance, Pharmacoepidemiology, and Drug Information Center Rennes University Hospital Rennes France

2. Laboratory of Experimental and Clinical Pharmacology Faculty of Medicine Rennes 1 University Rennes France

3. CIC‐P 1414 Clinical Investigation Center Inserm Rennes France

4. CIC‐P 1414 Clinical Investigation Center NUMECAN (Nutrition, Metabolism, and Cancer) Institute Inserm Rennes France

5. Department of Gastroenterology Rennes University Hospital Rennes France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1429

Reference30 articles.

1. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

2. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease

3. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

4. Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

5. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved high‐performance liquid chromatography tandem mass spectrometry method for quantification of infliximab in pediatric plasma and its application in therapeutic drug monitoring;Rapid Communications in Mass Spectrometry;2024-07-10

2. SERENE ER Analysis Part 2 SERENE‐UC: Exposure‐response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis;Clinical Pharmacology in Drug Development;2024-07-02

3. SERENE ER Analysis Part 1‐SERENE CD: Exposure‐Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease;Clinical Pharmacology in Drug Development;2024-07-02

4. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

5. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3